Skip to content

Process & Analytical Development

Expert Driven Drug Development

Quality by Design Process and Analytical Development

Developing robust manufacturing processes and analytical methods which reliably produce and quantify the critical characteristics of your product is paramount to seamlessly transitioning your therapy to cGMP manufacturing.

Whether your objective is to fast-track your current process or you’re taking your first steps towards cGMP, Landmark Bio’s robust menu of Process Development (PD) and Analytical Development (AD) Services will help to accelerate your advanced therapy to the clinic.

Landmark Bio’s comprehensive and phase-appropriate development services will safeguard the authenticity, integrity, and efficacy of your program and ensure cGMP-readiness

Process Development

The Landmark Bio laboratories and staff are armed with a diverse technology toolbox to enable, optimize and develop phase-appropriate cGMP-ready processes. The company’s expertise and toolbox include:

Purification and isolation of viral vectors, gene-modified cells, or other therapeutic products utilizing column/membrane chromatography, tangential flow filtration, depth filtration, and more.

Development, optimization and scale-up of cell culture processes, including selection of cell lines, media, bioreactor operating parameters, and growth conditions to maximize yield and quality of viral vectors or cell products.

Landmark Bio’s cell therapy services leverage next-generation capabilities and know-how to manipulate, scale and manufacture cell therapies for oncology, regenerative medicine, autoimmune disease and rare disease. Learn more

  • CAR-T and CAR-NK
  • iPSC-based
  • HSC
  • MSC
  • Organoids
  • Novel Cell Therapies
Landmark Bio has established a robust infrastructure to support contemporary viral manufacturing needs through a strategic combination of hands-on expertise, investments in advanced technology, and agile partnership models. Learn more.

  • Lentiviral Vector (LVV)
  • Adeno-associated virus (AAV)
  • Novel Viral Vectors
Landmark Bio has established a wide array of services to support the development and manufacturing of nanoparticle-based therapies. Learn more

  • Lipid nanoparticles (LNPs)
  • Inorganic nanoparticles
  • Extracellular Vesicles (EVs)

Analytical Development

Landmark Bio provides comprehensive Analytical Development Services to ensure phase-appropriate method development, qualification and verification. Our Analytical Development scientists leverage a deep toolbox of technologies suitable for a broad range of advanced therapy modalities.

Development, qualification and validation of assays
for purity, identity, potency and safety

Phenotypic (flow/nano flow cytometry), Molecular biology (PCR, electrophoresis, ELISA, UV/Vis, etc.), Biophysical (UPLC, particle analyzer, etc.)

In-process and release assay development

Development of in-process and release technologies

Custom assay development

Derisk and Accelerate your Advanced Therapy Program

Landmark Bio leverages wide-ranging PD and AD experience, and as your partner we will ensure an accelerated and derisked transfer of processes and methods to cGMP and Quality Control.

  • A fully streamlined process to ensure an efficient and derisked transfer to cGMP
  • AD team and QC Testing Laboratory operate under a single leadership model, derisking assay transfer
  • AD and QC Testing laboratories utilize equivalent instrumentation and equipment ensuring no instrument variability, thus reducing the risks and time required to transfer an analytical test method.
  • PD scientists work side-by-side with cGMP operators in the cGMP suite, profoundly reducing and mitigating the transfer risks and significantly reducing transfer time
Back To Top